AbbVie Inc. (ABBV)
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer
AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x only) can be attractive for deep value investors. The high yield and cheap valuation are for good reasons.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
AbbVie Inc. NYSE: ABBV delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an increase in its forward guidance. The results clear the way for ABBV stock to make $250 the new floor for the stock.
Why AbbVie Stock Flopped on Friday
Despite the pharmaceutical giant's beat-and-raise third quarter, investors were expecting better. Profitability guidance, even though it was raised, came in under analyst estimates.
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott Reents - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division David Amsellem - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Steve Scala - TD Cowen, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Luisa Hector - Joh.
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates
AbbVie (ABBV) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $3 per share a year ago.
5 Dividend ETFs That Could Pay You for Life
Whether you're just beginning to invest or sailing into retirement, you can benefit from a lifetime stream of passive income.
AbbVie Lifts Profit Outlook as Sales Rise
AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.
AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs
AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped boost third-quarter results above Wall Street estimates.
AbbVie: Deep Discount Before Earnings
AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is investing aggressively in R&D for future growth. The DDM model suggests ABBV is significantly undervalued, with a fair value estimate indicating 27% upside potential over the next year.
